Adam Simpson, Icosavax CEO
December 12, 2023 05:53 AM ESTUpdated 09:05 AM
Deals

As­traZeneca plunks down $800M+ up­front to buy vac­cine de­vel­op­er Icosavax and chal­lenge Pfiz­er, GSK in RSV

Amber Tong

As­traZeneca is shelling out $838 mil­lion up­front to ac­quire Icosavax and its pro­tein virus-like par­ti­cle plat­form tech­nol­o­gy in a move to add mus­cle to the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump picks vac­cine skep­tic Kennedy to lead HHS, in what would be an up­heaval of US health pol­i­cy

Eu­ro­pean drug reg­u­la­tor re­vers­es opin­ion on Ei­sai and Bio­gen's Alzheimer's drug

BeiGene will re­brand to BeOne Med­i­cines, drop­ping name's link to Chi­na roots

Gilead will close Philadel­phia, Seat­tle of­fices as part of job re­duc­tions

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times